Reduced synthesis or increased degradation of vascular nitric oxide contributes to endothelial dysfunction and plays a significant role in the development of atherosclerosis and other vascular diseases.
The product of nitric oxide (NO) synthase is the most potent endogenous vasodilator known. No not only is a potent vasodilator, it also inhibits platelet adherence and aggregation, reduces adherence of leukocytes to the endothelium, and suppresses proliferation of vascular smooth muscle cells. A number of disorders are associated with reduced synthesis and/or increased degradation of vascular NO. These include hypercholesterolemia, diabetes mellitus, hypertension, and tobacco use. The endothelial dysfunction caused by these disorders contributes to the alterations in vascular function and structure observed in these conditions. A reduction in the activity of vascular NO likely plays a significant role in the development of atherosclerosis. Insights into the mechanisms by which NO production or activity is altered in these states will lead to new therapeutic strategies in the treatment of a number of vascular disorders, including hypertension, atherosclerosis, restenosis, and thrombosis.
Cooke et al. (Sat,) conducted a review in Vascular Disease. Reduced synthesis or increased degradation of vascular nitric oxide contributes to endothelial dysfunction and plays a significant role in the development of atherosclerosis and other vascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: